Brief: Ocumension Therapeutics Says Phase III Clinical Trial Of Ot-301 (NCX 470) Approved In China
23/10/2020 16:29
Oct 23 (Reuters) - Ocumension Therapeutics 1477.HK :
* OT-301 (NCX 470) APPROVED BY CENTER FOR DRUG EVALUATION OF
NMPA
TO CARRY OUT ONE OF TWO PHASE III CLINICAL TRIALS
Source text https://bit.ly/3kpGScH
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application